1. Home
  2. OOMA vs PRTA Comparison

OOMA vs PRTA Comparison

Compare OOMA & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ooma Inc.

OOMA

Ooma Inc.

N/A

Current Price

$20.56

Market Cap

517.6M

Sector

Technology

ML Signal

N/A

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

N/A

Current Price

$9.25

Market Cap

449.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OOMA
PRTA
Founded
2003
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
517.6M
449.7M
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
OOMA
PRTA
Price
$20.56
$9.25
Analyst Decision
Strong Buy
Buy
Analyst Count
4
9
Target Price
$18.77
$19.00
AVG Volume (30 Days)
357.3K
421.9K
Earning Date
05-27-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
188.46
N/A
EPS
0.09
0.26
Revenue
$114,490,000.00
$814,000.00
Revenue This Year
$20.35
$1,111.38
Revenue Next Year
$4.17
N/A
P/E Ratio
$228.78
$36.23
Revenue Growth
9.53
N/A
52 Week Low
$9.79
$7.73
52 Week High
$22.72
$11.80

Technical Indicators

Market Signals
Indicator
OOMA
PRTA
Relative Strength Index (RSI) 45.83 54.92
Support Level $19.49 $8.83
Resistance Level $21.57 $9.36
Average True Range (ATR) 0.92 0.41
MACD -0.13 0.07
Stochastic Oscillator 14.41 67.98

Price Performance

Historical Comparison
OOMA
PRTA

About OOMA Ooma Inc.

Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that delivers voice and collaboration features, including messaging, intelligent virtual attendants, and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: